GSK plc (LON:GSK)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 59.94B |
| Revenue (ttm) | 31.53B |
| Net Income (ttm) | 3.15B |
| Shares Out | 4.05B |
| EPS (ttm) | 0.76 |
| PE Ratio | 19.44 |
| Forward PE | 8.70 |
| Dividend | 0.61 (4.11%) |
| Ex-Dividend Date | May 15, 2025 |
| Volume | 89,757 |
| Average Volume | 9,103,196 |
| Open | 1,482.50 |
| Previous Close | 1,485.50 |
| Day's Range | 1,464.86 - 1,485.50 |
| 52-Week Range | 1,242.50 - 1,678.68 |
| Beta | 0.27 |
| RSI | 52.01 |
| Earnings Date | Jul 28, 2025 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2024, GSK plc's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.
Financial StatementsNews
GSK announces the Linked by Lupus: Optimal Care Initiative to help support individuals with lupus in the US
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced the launch of the Linked by Lupus: Optimal Care Initiative to help support individuals impacted with lupus, particularly systemic...
GSK’s RSV vaccine to be reviewed by the EU for expanded use in adults
GSK says EU heath regulator reviewing expansion of RSV vaccine
GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its respiratory syncytial virus vaccine, Arexvy, to include adults from 18 years of age.
Bharat Biotech in-licences GSK's Shigella vaccine candidate
Bharat Biotech has in-licensed GSK's Shigella vaccine candidate, altSonflex1-2-3, aimed at combating Shigellosis in young children in low- and middle-income countries. Following promising early-stage ...
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
UW's School of Pharmacy receives $300K investment
The University of Waterloo’s School of Pharmacy announced Friday a partnership with multinational biopharma company GlaxoSmithKline (GSK) that will launch the Pharmacy Innovation in Immunization Resea...
Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million
Definitive agreement to result in one-time $225 million cash payment Theravance Biopharma retains rights to up to $150 million in milestones from Royalty Pharma on Trelegy Ellipta net sales in 2025 ...
Carat Group's Fred Hassan dives into what pharma companies to watch at 2025 ASCO Annual Meeting
Fred Hassan, Carat Group chairman, joins 'Money Movers' to discuss pharma innovation in 2025 and what companies he's watching in the sector.
Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday?
GSK and Spero ended a Phase 3 trial ... Full story available on Benzinga.com
Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday?
GSK plc GSK and Spero Therapeutics Inc SPRO on Wednesday announced that the pivotal phase 3 PIVOT-PO trial evaluating tebipenem HBr for complicated urinary tract infections (cUTIs) will stop early for...
GSK, Spero to stop urinary tract infection drug trial due to early success
Spero Therapeutics and partner GSK said on Wednesday that an experimental drug for complicated urinary tract infections met the main goal of a late-stage trial and the companies will be stopping the t...
Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee
If approved, tebipenem HBr could be the first oral carbapenem antibiotic for US patients with complicated urinary tract infections (cUTIs) An estimated 2.9 million cases of cUTIs are treated annually ...
GSK shares break six-session winning streak
GSK wins EU backing for multiple myeloma drug, Blenrep
Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD)
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult pat...
GSK wins FDA label expansion for asthma therapy Nucala in COPD
GSK's asthma drug Nucala wins FDA's approval to treat 'smoker's lung'
The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic lung disease commonly known as "smoker's lung", the company said on Thursda...
Pharma stocks rally: Glaxo surges 7%, Torrent gains after Q4; Gland steady post mixed results
Pharma stocks were trading firmly in the green on Tuesday morning, with GlaxoSmithKline Pharmaceuticals leading the charge—rising 7.4% to ₹2,992.80 as of 10:05 AM. The broader sector saw widespread bu...
GSK's Blood-Cancer Treatment Combinations Approved in Japan
The pharma company said it expects more approvals through the year following positive results from a Phase 3 trial.
Notable healthcare headlines for the week: UnitedHealth, Novo Nordisk and GSK in focus
The S&P 500 Health Care Index Sector (XLV) slipped 4.05% during the week.
iTeos Therapeutics: End To Belrestotug Program Leads To A Hold Rating
iTeos Therapeutics downgraded to Hold after belrestotug failure and GSK deal ending. Read my updated analysis on ITOS stock here.
GSK To Buy Phase-3 Ready Liver Disease Drug For Up To $2 Billion
GSK plc (NYSE: GSK) on Wednesday agreed to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa . Under the agreement, GSK will pay up to $2 billion in total cash consideration. This include...
GSK to buy phase III-ready drug efimosfermin from Boston Pharmaceuticals for as much as $2B
GSK Buys Liver-Disease Treatment From Boston Pharmaceuticals for Up to $2 Billion
The pharma giant will pay $1.2 billion up-front for efimosfermin, with deal including potential success-based milestone payments of $800 million.
GSK to buy efimosfermin for up to $2 billion
British pharmaceutical giant GSK on Wednesday said it will buy efimosfermin, a phase III-ready potential specialty medicine from Boston Pharmaceuticals, for up to $2 billion.